News Briefs
✦ CVS Health Corp. said on March 31 that its PBM division Caremark will “continue to serve the government-wide Service Benefit Plan” in a deal effective Jan. 1, 2022. The contract is an arrangement with carriers of the Federal Employees Health Benefits program and adds specialty drug management to Caremark’s existing contract providing retail, mail and clinical pharmacy services. Prime Therapeutics LLC previously held the specialty contract. Read more at https://bit.ly/3t11yfk.
✦ After replacing Novartis’ psoriasis drug Cosentyx (secukinumab) with Eli Lilly and Co.’s Taltz (ixekizumab) on most of its 2021 formularies, Cigna Corp. is offering a financial incentive for recalcitrant patients to switch to the cheaper drug. In March, the insurer sent a letter advising doctors that patients could receive a $500 debit card if they switch from Cosentyx to Taltz or an older biologic before Aug. 31 and then refill the prescription before Dec. 31, according to the American Journal of Managed Care. Visit https://bit.ly/3wBh0kJ.
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile
